In late December 2025, Sanofi secured European Commission approval for Wayrilz (rilzabrutinib), the first BTK inhibitor for ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

Ascentage Pharma receives US FDA’s IND clearance for BTK degrader APG-3288 to treat patients with relapsed/refractory B-cell malignancies: Rockville, Maryland Friday, January 9, ...

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the body’s nerves. Immune cells ...

Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, ...

Ascentage Pharma Group International has obtained IND approval from the FDA for its BTK-targeted protein degrader APG-3288. A phase I study will be conducted in patients with relapsed or refractory ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

New findings reveal promising advancements in treating relapsed mantle cell lymphoma with BCL-2 inhibitors and novel agents, ...

A new study led by the University of Toronto (U of T) has discovered a possible biomarker linked to multiple sclerosis (MS) ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...